MorphoSys Corp (MOR) Net earnings per share growth forecast for next year
MorphoSys AG (MOR) develops innovative antibodies to combat lymphomas, targeting the global immunotherapy market. The consensus forward EPS growth forecast visualizes the dynamics of these expectations, where 34.80 describes the current status of the metric. A strategic focus on its lead drug and the Novartis acquisition have secured a premium valuation, while unique blood therapy patents have established a powerful defensive moat.
morphosys.com - analytical breakdowns and key metrics (MOR)
- price and consensus price forecast:
- market capitalization details:
- company book value details:
- issuer credit burden and liquidity indicators:
- net income and valuation ratios data:
MOR - Net Financial Result|Future Profit MorphoSys AG|MOR - Company Value to Net Income|Forward P/E Multiple MorphoSys AG|MOR - PEG Multiple|EV/EBITDA Multiple MorphoSys|MOR - Operating profit before depreciation charges|Earnings per share for the last twelve months MorphoSys|MOR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months morphosys.com|MOR - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year MorphoSys AG
Fundamental company analysis:MOR, MorphoSys Corp
The preservation of the research and development potential of MorphoSys AG (MOR) with the support of Novartis guarantees stability in the development of oncology drugs. The trend in expected earnings per share growth reflects the daily reassessment of institutional net income forecasts, allowing investors to identify real market interest in the asset and avoid buying at the peak following earnings reports, which is critical for this class of high-tech securities.
Competitor analysis
Net earnings per share growth forecast for next year BeiGene Corp|Expected earnings per share growth for next year Halozyme Corp (HALO)|Net earnings per share growth forecast for next year Revolution Medicines (RVMD)|AAPG - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year CG Oncology CGON|Expected earnings per share trend next year URGN|BCAX - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PSNL|ERAS: Earnings growth forecast for next year|delcath.com - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics, Inc.|Expected net earnings per share growth next year Aura Biosciences Inc AURA|Net earnings per share growth forecast for next year Candel Therapeutics (CADL)|Consensus forecast of earnings per share growth for next year Accuray, Inc.|SELLAS Life Sciences Group - Expected earnings per share growth for next year|actuatetherapeutics.com (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year TuHURA Biosciences, Inc. HURA|TARA (Protara) - Expected earnings per share growth for next year|Fate Pharma - Expected earnings per share trend next year|WHWK (Aadi Bioscience, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year TScan|Earnings growth forecast for next year CSBR|xbiotech.com (XBIT) - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|OSTX - Expected earnings per share growth for next year|RADX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics, Inc.|adlainortye.com (ANL) - Net earnings per share growth forecast for next year|Veru Inc - Expected earnings per share trend next year|TPST (Tempest Tx) - Earnings growth forecast for next year|Expected earnings per share growth for next year Xilio (XLO)|Earnings growth forecast for next year RENB|Earnings growth forecast for next year muraloncology.com (MURA)|Net earnings per share growth forecast for next year Kairos Pharma KAPA|OKUR: Projected earnings per share growth rate for next year|CytoMed - Earnings growth forecast for next year|Curis, Inc. (CRIS) - Expected earnings per share growth for next year|APLM: Earnings growth forecast for next year|Expected net earnings per share growth next year tharimmune.com (THAR)|Net earnings per share growth forecast for next year Advanced Biomed Inc.|GNPX: Expected earnings per share trend next year|Expected earnings per share growth for next year CLDI (Calidi Biotherapeutics)|SBFM (Sunshine Biopharma Inc.) - Expected earnings per share trend next year|Earnings growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|SLRX - Expected earnings per share growth for next year|PPBT: Expected earnings per share growth for next year|AONC - Earnings growth forecast for next year|BeOne Medicines (BGNE) - Net earnings per share growth forecast for next year|Checkpoint Therapeutics Inc - Expected earnings per share trend next year|ELEV (Elevation Oncology, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year iCAD Corp ICAD|Net earnings per share growth forecast for next year Ikena Oncology, Inc. (IKNA)|Expected earnings per share growth for next year Notable Labs Ltd NTBL|Net earnings per share growth forecast for next year Viracta Therapeutics, Inc. VIRX|NAYA Biosciences Corp (NAYA) - Expected net earnings per share growth next year|AAPGV - Net earnings per share growth forecast for next year
